Vaxart, Inc. (VXRT): Nasdaq/NYSE listing notice — Vaxart receives $9.27M BARDA award for Phase 2b COVID pill vaccine; Nasdaq extends bid price compliance to July 2024

Vaxart, Inc.

Vaxart awarded $9.27M from BARDA Project NextGen to prepare for a 10,000-subject Phase 2b study of its oral XBB COVID-19 vaccine vs. an approved mRNA comparator.
Project NextGen is a $5B HHS initiative to develop innovative COVID vaccines and therapeutics providing broader, more durable protection.
Nasdaq granted an additional 180-day compliance period until July 15, 2024 to meet the $1.00 minimum bid price requirement.
Vaxart is considering options, including a reverse stock split, to regain compliance; no assurance of success is given.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vaxart, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

en notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Notice did not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company originally had 180 calendar days, or until January 17, 2024, to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. Pursuant to the Extension Letter, the Company now has until July 15, 2024

View on SEC.gov

Browse all listing & compliance notices →

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-001757

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.